Core Viewpoint - Ruian Gene (688217.SH) faces dual setbacks as its actual controllers are sued for fraud, and the company forecasts a significant revenue drop for 2025, indicating a severe decline in financial performance and trust [2][10]. Group 1: Company Background - Ruian Gene was founded by actual controllers Xiong Hui and Xiong Jun, who have impressive academic backgrounds and initially developed a clinical HBV drug resistance testing kit, filling a technological gap in the market [5]. - The company went public on the STAR Market in May 2021, becoming a star in precision medicine due to its technological advantages in leukemia detection, with the controlling family holding over 30% of the shares [5][6]. Group 2: Fraud Allegations and Investigation - The fraud investigation began in July 2021 when the Shenzhen Medical Insurance Bureau received reports of employees from AstraZeneca allegedly altering cancer patient gene test results to fraudulently obtain insurance reimbursements [6][9]. - Ruian Gene was implicated as a key player in the fraud chain, with its subsidiary Wuhan Sitai being mentioned in court proceedings regarding the manipulation of test results [9][10]. Group 3: Financial Performance and Forecast - The company forecasts a revenue of only 170 million to 176 million yuan for 2025, representing a year-on-year decline of 27.36% to 29.84%, with net losses expected to widen to between 39.91 million and 59.86 million yuan [2][12]. - The core business of molecular diagnostic reagent sales has been severely impacted, with a nearly 20% decline in revenue in the first half of 2025, and the testing service business experiencing a 30.2% drop in revenue [13][15]. Group 4: Governance and Management Response - Following the legal troubles of the actual controllers, the company's governance structure has not changed significantly, with Xiong Hui resigning from her positions in September 2025 but her husband quickly taking over [10][18]. - Despite ongoing financial losses and the legal issues, the company approved a cash dividend of 1.7 yuan per 10 shares, reflecting a disconnect between management decisions and financial realities [17][18]. Group 5: Industry Implications - The situation at Ruian Gene serves as a cautionary tale for the precision medicine industry, emphasizing the importance of trust and integrity in maintaining market position and customer relationships [20].